SAGE Therapeutics (SAGE) Posts Q4 Loss of ~$1.57/Share

SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of about ($1.57), $1.13 worse than the analyst estimate of ($0.44).

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Goldman "broadly" raises estimates for LTL and truckload stocks
• SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 17, 2026 in Sportradar Group AG Lawsuit - SRAD